Company intelligence / Profile preview
Usynova Pharmaceuticals
Shanghai, Shanghai, Chinaen.usynova.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Early proof-of-concept results for UA007 have been achieved in ongoing phase II studies for both gouty arthritis and chemotherapy-induced diarrhea. The company reports that current treatments for these indications often have resistance or side effects, with CID lacking effective therapies entirely. For the oncology asset UA022 targeting KRASG12D mutations—prevalent across multiple cancers—potent anti-cancer activity and favorable safety were demonstrated in pre-clinical models prior to outlicensing to AstraZeneca.
- Therapeutic areas
- OncologyRheumatologyImmunology
- Modalities
- Small moleculesBiologics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
AstraZeneca – exclusive global license agreement for KRASG12D inhibitor UA022Insilico Medicine – strategic partnership on AI-driven R&D of innovative drugsWuXi AppTec participated in discovery/validation process of UA022
Beyond the preview
Go deeper on Usynova Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Usynova Pharmaceuticals.